CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- 4 Open-market sale Chief Scientific Officer sold 2,650 shares at an average $52.06 ($137,965)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Scientific Officer sold 2,650 shares at an average $53.75 ($142,447)
- 4 Open-market sale Chief Scientific Officer sold 2,650 shares at $60.00 ($159,000)
- 4 Open-market sale Director sold 47,651 shares at an average $57.84 ($2,756,116)
- 4 Open-market sale Chief Scientific Officer sold 2,650 shares at an average $50.40 ($133,558)
- 4 Open-market sale Director sold 47,651 shares at an average $54.09 ($2,577,376)
- 4 Open-market sale Chief Scientific Officer sold 21,200 shares at an average $59.91 ($1,270,058)
- 4 Open-market sale Chief Scientific Officer sold 10,600 shares at $50.00 ($530,000)
- 4 Open-market sale Director sold 47,651 shares at an average $42.12 ($2,007,129)
- 4 Open-market sale Director sold 8,598 shares at an average $38.20 ($328,441)
- 4 Open-market sale Director sold 26,367 shares at an average $38.56 ($1,016,653)
- 4 Open-market sale Director sold 12,686 shares at an average $40.10 ($508,755)
- 4 Open-market sale Director sold 95,302 shares at an average $41.17 ($3,924,003)
- 4 Option exercise Chief Scientific Officer acquired 1,293 shares (option exercise)
Page 7 of 11 · 207 filings